Microtubule-associated Protein 4 is an Important Regulator of Cell Invasion/migration and a Potential Therapeutic Target in Esophageal Squamous Cell Carcinoma

Overview

Journal Oncogene

Specialties Molecular Biology
Oncology

Date 2016 Feb 16

PMID 26876215

Citations 25

Authors

Y-Y Jiang

L Shang

Z-Z Shi

T-T Zhang

S Ma

C-C Lu

Y Zhang

J-J Hao

C Shi

F Shi

X Xu

Y Cai

X-M Jia

Q-M Zhan

M-R Wang

Affiliations

Soon will be listed here.

Abstract

Cell invasion and migration significantly contribute to tumor metastasis. Microtubule-associated protein 4 (MAP4) protein is one member of microtubule-associate proteins family. It is responsible for stabilization of microtubules by modulation of microtubule dynamics. However, there is little information about the involvement of MAP4 in human cancer. Here we show that MAP4 serves as a regulator of invasion and migration in esophageal squamous cancer cells. By activating the ERK-c-Jun-vascular endothelial growth factor A signaling pathway, MAP4 promotes cell invasion and migration in vitro, tumor growth and metastasis in mouse models. Immunohistochemical staining of operative tissues indicated that MAP4 expression was associated with tumor stage, lymph node metastasis and shorter survival of the patients with esophageal squamous cell carcinoma (ESCC). Multivariate Cox regression analysis showed that MAP4 is an independent prognostic indicator. In the serial sections of ESCC tissues, there was a positive correlation between MAP4 and vascular endothelial growth factor A expression. Notably, an intratumoral injection of MAP4-small interfering RNA (siRNA) remarkably inhibited the growth of the tumors that formed by the MAP4-expressing ESCC cells in nude mice, and a combination of MAP4-siRNA and Bevacizumab significantly enhanced the inhibition effect. Our data suggest that MAP4 is probably a useful prognostic biomarker and a potential therapeutic target for the disease.

Citing Articles

cGAS-ISG15-RAGE axis reprogram necroptotic microenvironment and promote lymphatic metastasis in head and neck cancer.

Li J, Tan J, Wang T, Yu S, Guo G, Li K Exp Hematol Oncol. 2024; 13(1):63.

PMID: 38926796 PMC: 11200990. DOI: 10.1186/s40164-024-00531-5.

A p85 isoform switch enhances PI3K activation on endosomes by a MAP4- and PI3P-dependent mechanism.

Thapa N, Chen M, Cryns V, Anderson R Cell Rep. 2024; 43(5):114119.

PMID: 38630589 PMC: 11380499. DOI: 10.1016/j.celrep.2024.114119.

MAP4 acts as an oncogene and prognostic marker and affects radioresistance by mediating epithelial-mesenchymal transition in lung adenocarcinoma.

Xia X, Ge Y, Ge F, Gu P, Liu Y, Li P J Cancer Res Clin Oncol. 2024; 150(2):88.

PMID: 38341398 PMC: 10858930. DOI: 10.1007/s00432-024-05614-8.

The platinum coordination complex inhibits cell invasion-migration and epithelial-to-mesenchymal transition by altering the TGF-β-SMAD pathway in colorectal cancer.

Abdulla M, Alzailai A, Vaali-Mohammed M, Ahmad R, Fatima S, Zubaidi A Front Pharmacol. 2023; 14:1178190.

PMID: 38027033 PMC: 10679924. DOI: 10.3389/fphar.2023.1178190.

Elevated expression of the RNA-binding protein IGF2BP1 enhances the mRNA stability of INHBA to promote the invasion and migration of esophageal squamous cancer cells.

Wang J, Chen D, Zhang Y, Xu X, Cai Y, Wei W Exp Hematol Oncol. 2023; 12(1):75.

PMID: 37644505 PMC: 10466848. DOI: 10.1186/s40164-023-00429-8.

References

Soker S, Vlodavsky I, Neufeld G . The binding of vascular endothelial growth factor to its receptors is dependent on cell surface-associated heparin-like molecules. J Biol Chem. 1992; 267(9):6093-8. View

Deng Z, Sui G, Rosa P, Zhao W . Radiation-induced c-Jun activation depends on MEK1-ERK1/2 signaling pathway in microglial cells. PLoS One. 2012; 7(5):e36739. PMC: 3351464. DOI: 10.1371/journal.pone.0036739. View

Gerber H, McMurtrey A, Kowalski J, Yan M, Keyt B, Dixit V . Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3'-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation. J Biol Chem. 1998; 273(46):30336-43. DOI: 10.1074/jbc.273.46.30336. View

Tekedereli I, Alpay S, Akar U, Yuca E, Ayugo-Rodriguez C, Han H . Therapeutic Silencing of Bcl-2 by Systemically Administered siRNA Nanotherapeutics Inhibits Tumor Growth by Autophagy and Apoptosis and Enhances the Efficacy of Chemotherapy in Orthotopic Xenograft Models of ER (-) and ER (+) Breast Cancer. Mol Ther Nucleic Acids. 2013; 2:e121. PMC: 4028016. DOI: 10.1038/mtna.2013.45. View

Hu J, Chu Z, Han J, Dang Y, Yan H, Zhang Q . The p38/MAPK pathway regulates microtubule polymerization through phosphorylation of MAP4 and Op18 in hypoxic cells. Cell Mol Life Sci. 2009; 67(2):321-33. PMC: 11115776. DOI: 10.1007/s00018-009-0187-z. View

Feng Y, Lin D, Shi Z, Wang X, Shen X, Zhang Y . Overexpression of PLK1 is associated with poor survival by inhibiting apoptosis via enhancement of survivin level in esophageal squamous cell carcinoma. Int J Cancer. 2008; 124(3):578-88. DOI: 10.1002/ijc.23990. View

Lee W, Chen W, Wang C, Lin W, Tseng T . Apigenin inhibits HGF-promoted invasive growth and metastasis involving blocking PI3K/Akt pathway and beta 4 integrin function in MDA-MB-231 breast cancer cells. Toxicol Appl Pharmacol. 2007; 226(2):178-91. DOI: 10.1016/j.taap.2007.09.013. View

Kremer B, Haystead T, Macara I . Mammalian septins regulate microtubule stability through interaction with the microtubule-binding protein MAP4. Mol Biol Cell. 2005; 16(10):4648-59. PMC: 1237071. DOI: 10.1091/mbc.e05-03-0267. View

Chen H, Gore-Langton R, Cheson B . Clinical trials referral resource: Current clinical trials of the anti-VEGF monoclonal antibody bevacizumab. Oncology (Williston Park). 2001; 15(8):1017, 1020, 1023-6. View

10.

Murphy M, Hinman A, Levine A . Wild-type p53 negatively regulates the expression of a microtubule-associated protein. Genes Dev. 1996; 10(23):2971-80. DOI: 10.1101/gad.10.23.2971. View

11.

Shibuya M . Differential roles of vascular endothelial growth factor receptor-1 and receptor-2 in angiogenesis. J Biochem Mol Biol. 2006; 39(5):469-78. DOI: 10.5483/bmbrep.2006.39.5.469. View

12.

He Y, Hou J, Chen Z, Qiao C, Song G, Meng F . Decrease in the esophageal cancer incidence rate in mountainous but not level parts of Cixian County, China, over 29 years. Asian Pac J Cancer Prev. 2006; 6(4):510-4. View

13.

Chang W, Gruber D, Chari S, Kitazawa H, HAMAZUMI Y, Hisanaga S . Phosphorylation of MAP4 affects microtubule properties and cell cycle progression. J Cell Sci. 2001; 114(Pt 15):2879-87. DOI: 10.1242/jcs.114.15.2879. View

14.

Fruchon S, Kheirallah S, Al Saati T, Ysebaert L, Laurent C, Leseux L . Involvement of the Syk-mTOR pathway in follicular lymphoma cell invasion and angiogenesis. Leukemia. 2011; 26(4):795-805. DOI: 10.1038/leu.2011.248. View

15.

Ferrara N, Gerber H, LeCouter J . The biology of VEGF and its receptors. Nat Med. 2003; 9(6):669-76. DOI: 10.1038/nm0603-669. View

16.

Enzinger P, Mayer R . Esophageal cancer. N Engl J Med. 2003; 349(23):2241-52. DOI: 10.1056/NEJMra035010. View

17.

Gerber H, Dixit V, Ferrara N . Vascular endothelial growth factor induces expression of the antiapoptotic proteins Bcl-2 and A1 in vascular endothelial cells. J Biol Chem. 1998; 273(21):13313-6. DOI: 10.1074/jbc.273.21.13313. View

18.

Huang S, Robinson J, Deguzman A, Bucana C, Fidler I . Blockade of nuclear factor-kappaB signaling inhibits angiogenesis and tumorigenicity of human ovarian cancer cells by suppressing expression of vascular endothelial growth factor and interleukin 8. Cancer Res. 2000; 60(19):5334-9. View

19.

Brock A, Krause S, Li H, Kowalski M, Goldberg M, Collins J . Silencing HoxA1 by intraductal injection of siRNA lipidoid nanoparticles prevents mammary tumor progression in mice. Sci Transl Med. 2014; 6(217):217ra2. PMC: 5546412. DOI: 10.1126/scitranslmed.3007048. View

20.

Kappas N, Zeng G, Chappell J, Kearney J, Hazarika S, Kallianos K . The VEGF receptor Flt-1 spatially modulates Flk-1 signaling and blood vessel branching. J Cell Biol. 2008; 181(5):847-58. PMC: 2396811. DOI: 10.1083/jcb.200709114. View